17 January 2020 - A Boston-based biotech startup thinks it has found a lucrative third way between high-margin branded drugs and high-volume generics.

A biotech startup wants to make me-too versions of existing drugs. So far, so familiar. Except that eqrx, a firm based in Boston, aims to launch ten high-end medicines, including for cancer, in ten years—quite a feat by the industry’s sluggish standards. More unusual, it wants to charge a third of the price of rival treatments, maybe less. 

On 12 January it announced $200m in funding from investors that included Alphabet’s venture arm and Andreessen Horowitz, a famed Silicon Valley finance firm, which gushed that eqrx promised to “reimagine how medicines are created, tested and commercialised”.

Read The Economist article